S. Wadhwa

A recombinant luteinising-hormone-releasing-hormone immunogen bioeffective in causing prostatic atrophy.

Mushir M. Ali, K. Raina, Ruma Ray, 2004, Vaccine.

Vaccines and Antibodies for Therapeutic Use in Cancers

M. Diwan, J. C. Gupta, G. P. Talwar, 2016 .

Conjugation to a Carrier Renders a Self Molecule Immunogenic besides Imparting Immuno-Prophylactic Benefit

R. Naz, G. P. Talwar, J. C. Gupta, 2016 .

Immunohistochemical localization of transforming growth factor-alpha, epidermal growth factor receptor and c-erbB-2 protein in hyperplastic human prostates.

D. Giri, R. Pal, G. P. Talwar, 1995, Carcinogenesis.

Treatment outcomes of germ cell tumors of ovary: Single institutional study

S. Gargy, Mukunda Kumar, R. Jha, 2021, Journal of Oncology Research.

Androgen, estrogen, and progesterone receptor contents and serum hormone profiles in patients with benign hypertrophy and carcinoma of the prostate

Vijay Kumar, Vijay L Kumar, V. Kumar, 1990, Journal of surgical oncology.

Misdiagnosis of Li-Fraumeni Syndrome in a Patient With Clonal Hematopoiesis and a Somatic TP53 Mutation.

Ritu Ghai, J. Rotmensch, L. Buckingham, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

Misdiagnosis of Li-Fraumeni Syndrome in a Patient With Clonal Hematopoiesis and a Somatic TP53 Mutation.

Ritu Ghai, J. Rotmensch, L. Buckingham, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.